MedTrace Logo

A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris

NCT01347255 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-03-07

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to evaluate the anti-psoriatic effect of LEO 90100 cutaneous spray ointment, using the psoriasis plaque test modified from the method developed by KJ Dumas and JR Scholtz.

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

LEO90100 cutaneous spray, ointment

once daily application, 4 weeks

DRUG

LEO 90100 cutaneous spray, ointment, vehicle with betamethasone dipropionate

once daily application, 4 weeks

DRUG

LEO 90100 cutaneous spray, ointment, vehicle

once daily application, 4 weeks

DRUG

Daivobet® ointment

once daily application, 4 weeks

Sponsors & Collaborators

  • LEO Pharma

    lead INDUSTRY

Principal Investigators

  • Catherine Queille-Roussel, MD · Centre de Pharmacologie Clinique Appliquée à la Dermatologie (CPCAD), Hôpital l'Archet 2, 06202 Nice Cedex 3, France

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01347255 on ClinicalTrials.gov